Protagonist Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 112

Market Cap: $2.4B

Website

Introduction: Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Clinical Trials

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Phase 3

Conditions: Polycythemia Vera

Interventions: Drug: Open-label rusfertide

First Posted Date: 2023-09-13

Last Posted Date: 2024-07-17

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 50

Registration Number: NCT06033586

Locations: 🇺🇸
Pontchartrain Cancer Care, Covington, Louisiana, United States

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Phase 3

Active, not recruiting

Conditions: Polycythemia Vera

Interventions: Drug: Placebo
Drug: Rusfertide

First Posted Date: 2022-01-27

Last Posted Date: 2024-07-17

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 250

Registration Number: NCT05210790

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
Good Samaritan Infusion Center - Thomas, Cincinnati, Ohio, United States

and more 168 locations

Pharmacokinetics of PN-232 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: PN-232
Drug: Placebo

First Posted Date: 2021-03-29

Last Posted Date: 2022-10-03

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 48

Registration Number: NCT04819620

Locations: 🇦🇺
Protagonist Study Site, Nedlands, Western Australia, Australia
🇦🇺
Protagonist Clinical Site, Adelaide, South Australia, Australia

PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Phase 2

Completed

Conditions: Polycythemia Vera

Interventions: Drug: PTG-300

First Posted Date: 2021-02-23

Last Posted Date: 2024-03-18

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT04767802

Locations: 🇰🇷
Seoul St. Mary's Catholic University Hospital, Seoul, Korea, Republic of
🇲🇾
Hospital Raja Permaisuki Bainun, Ipoh, Perak, Malaysia
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 5 locations

Pharmacokinetics of PN-235 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PN-235
Drug: Placebo

First Posted Date: 2020-11-09

Last Posted Date: 2022-02-18

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 107

Registration Number: NCT04621630

Locations: 🇦🇺
Nucleus Network Melbourne Clinic, Melbourne, Australia

Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PTG-300

First Posted Date: 2020-08-18

Last Posted Date: 2021-09-16

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 12

Registration Number: NCT04516382

Locations: 🇦🇺
Protagonist Clinical Center, Melbourne, Australia

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Phase 2

Completed

Conditions: Ulcerative Colitis Chronic Moderate
Ulcerative Colitis Chronic Severe

Interventions: Drug: PN-943
Drug: Placebo

First Posted Date: 2020-08-07

Last Posted Date: 2023-04-25

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 169

Registration Number: NCT04504383

Locations: 🇰🇷
Protagonist Investigational site, Seoul, Korea, Republic of
🇺🇦
Protagonist Investigational Site, Zhytomyr, Ukraine

PTG-300 in Subjects With Hereditary Hemochromatosis

Phase 2

Completed

Conditions: Hereditary Hemochromatosis

Interventions: Drug: PTG-300

First Posted Date: 2019-12-18

Last Posted Date: 2023-06-15

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT04202965

Locations: 🇨🇦
Protagonist Investigational Site, Toronto, Ontario, Canada

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

Phase 2

Active, not recruiting

Conditions: Polycythemia Vera

Interventions: Drug: PTG-300
Drug: Placebo

First Posted Date: 2019-08-14

Last Posted Date: 2023-11-15

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 80

Registration Number: NCT04057040

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
Mayo Clinic - Mayo Clinic Hospital, Phoenix, Arizona, United States

and more 13 locations

Safety Study for Beta Thalassemia Subjects on PTG-300

Phase 2

Completed

Conditions: β-thalassemia
Ineffective Erythropoiesis

Interventions: Drug: PTG-300

First Posted Date: 2019-08-13

Last Posted Date: 2021-07-16

Lead Sponsor: Protagonist Therapeutics, Inc.

Target Recruit Count: 34

Registration Number: NCT04054921

Locations: 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇬🇷
Laiko General Hospital of Athens, Athens, Greece

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy